Collegium Pharmaceutical, Inc (COLL) stock
COLLNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 10/3045% below fair value
$24.95+0.14 (+0.56%)
Close on Nov 12, 2026Market cap $812.26MP/E 24.9Yield –
Collegium Pharmaceutical price to sales ratio
The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.
Collegium Pharmaceutical's price to sales ratio was 1.0× on Nov 11, 2026, against 1.9× a year earlier. Over the last 5 years it ranged from 0.9× to 2.6×, with a median of 1.7×.
Price to Sales Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 11, 2026 | 1.0× | −0.9 |
| 2025 | Dec 31, 2025 | 1.9× | +0.4 |
| 2024 | Dec 31, 2024 | 1.5× | −0.3 |
| 2023 | Dec 29, 2023 | 1.9× | −0.3 |
| 2022 | Dec 30, 2022 | 2.2× | +0.2 |
| 2021 | Dec 31, 2021 | 2.0× | −0.3 |
| 2020 | Dec 31, 2020 | 2.2× | −0.1 |
| 2019 | Dec 31, 2019 | 2.3× | −0.3 |
| 2018 | Dec 31, 2018 | 2.6× | −27.3 |
| 2017 | Dec 29, 2017 | 29.9× | – |
See a number that looks wrong?